Email Updates

Search form

You are here

AVAC in the News

  • Six short videos describe how a Kenyan nonprofit organization tackles one of Africa’s toughest missions: helping young women protect themselves against HIV.

    December 15, 2017
    The New York Times
  • AVAC Policy Director Kevin Fisher appeared on CGTN to discuss the role of governments and private industry in addressing prevention, the search for a cure, and overall costs.

    December 6, 2017
    CGTN America
  • About a dozen new types of microbicides are in the research pipeline, including some that could protect women against not only HIV infection but also other sexually transmitted infections and unwanted pregnancies. But this progress is in peril.

    November 23, 2017
    Bhekisisa
  • Describing the value of working with funders, sponsors, industry partners, governments and community members during all stages of tuberculosis vaccine research and development, the Good Participatory Practice Guidelines for TB Vaccine Research released the first day of this conference is the latest step in a movement to ensure those most affected by science inform its discoveries.

    October 17, 2017
    General
    Science Speaks
  • With the annual IDWeek conference fast approaching, thousands of leading physicians and researchers will once again gather to learn about cutting-edge research on HIV prevention, treatment and cures -- and to discuss how to apply that research in ways that can directly benefit people living with HIV today.

    September 29, 2017
    BodyPro
  • A clinical trial published in the Lancet showed a new injectable antiretroviral therapy (ART) given every four or eight weeks may be just as effective as the daily oral medications that are currently used to keep the virus under control.

    August 17, 2017
    Healthline
  • Thirty-six years after a rare lung infection in gay men in Los Angeles heralded the start of the AIDS epidemic... more than half of all people living with HIV are on virus-suppressing treatment... And thousands of people are using Gilead Sciences Inc.’s Truvada in the PrEP trial that’s curbing the spread in communities from London to San Francisco.

    August 17, 2017
    Bloomberg
  • Last fall, Gilead came under fire from community activists for rolling out the DISCOVER trials for Descovy (TAF/FTC) as PrEP without adequately involving community advisors per the Good Participatory Practice (GPP) guidelines. Community advocate and clinical investigator pushback led to some changes in the trial protocol, [but]...according to Jeremiah Johnson, community engagement coordinator for Treatment Action Group (TAG),...other concerns remain.

    August 7, 2017
    The Body
  • Healthcare giant Johnson & Johnson is to take a big step closer to inventing a vaccine for HIV when it publishes the results of a groundbreaking clinical trial this week.

    July 23, 2017
    Telegraph
  • As the world's top HIV experts head to Paris for an International AIDS Society meeting, word is we're still playing catch-up with the virus. And if resistance to antiretroviral drugs grows, things will only get worse.

    July 20, 2017
    Deutsche Welle

Pages